middle.news
How Is Chimeric Therapeutics Navigating Clinical Success Amid Cash Pressure?
6:17pm on Friday 31st of October, 2025 AEDT
•
Healthcare
Read Story
How Is Chimeric Therapeutics Navigating Clinical Success Amid Cash Pressure?
6:17pm on Friday 31st of October, 2025 AEDT
Key Points
CHM CDH17 trial escalates to dose level 2 with manageable safety profile
57% clinical response rate in high-risk AML patients in CHM CORE-NK study
Appointment of Professor Miles Prince as Non-Executive Director
Letter of Intent signed with Viral Vector Manufacturing Facility for local lentiviral vector production
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CHM
OPEN ARTICLE